Resverlogix Corp. (RVX.TO)
| Previous Close | 0.3000 |
| Open | 0.3450 |
| Bid | 0.2900 x 0 |
| Ask | 0.3000 x 0 |
| Day's Range | 0.3000 - 0.3450 |
| 52 Week Range | 0.2800 - 0.9500 |
| Volume | |
| Avg. Volume | 47,971 |
| Market Cap | 72.786M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 21.43 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients. The meeting is scheduled for early August. In response to the transformation of the COVID-19 pandemic, advancement to the Pha
- GlobeNewswire
Resverlogix Announces One-Year Extension of Debenture
CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023. “We are extremely pleased that our partner Hepalink has extended the debenture’s maturity date. This speaks volume
- GlobeNewswire
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an impact factor of 21.4. The article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p. The
